Pharmaceutical composition for preventing or treating arthritis
N-dodecyl-4-hydroxybenzamide-based compositions inhibit synovial fibroblasts and macrophages to suppress arthritis progression, offering a safer and more effective treatment by targeting key inflammatory cells.
Patent Information
- Application Number
- KR1020250058133
- Authority / Receiving Office
- KR · KR
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-05-02
- Publication Date
- 2026-11-10
AI Technical Summary
Current arthritis treatments, such as NSAIDs, steroids, and immunosuppressants, have limitations including side effects and cannot fundamentally inhibit the progression of the disease, while there is a need for safer and more effective treatments that target the causative cells of arthritis.
A pharmaceutical composition containing N-dodecyl-4-hydroxybenzamide, its pharmaceutically acceptable salts, hydrates, or solvates, which inhibits the differentiation and activity of synovial fibroblasts and macrophages, key cells involved in arthritis progression, by reducing the expression of cytokines like RANKL, IL-1b, IL-6, TNF-α, and iNOS.
The composition effectively suppresses inflammation and delays the onset of arthritis by inhibiting the activity of synovial fibroblasts and macrophages, providing a safer and more effective treatment option.
Smart Images

Figure PAT00010_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a pharmaceutical composition for the prevention or treatment of arthritis. Background Technology
[0002] Arthritis is a disease characterized by inflammation of the joints, accompanied by symptoms such as pain, swelling, stiffness, and limited movement. Arthritis is broadly classified into osteoarthritis and rheumatoid arthritis, but various other types exist, including gouty arthritis and psoriatic arthritis. In particular, osteoarthritis is a degenerative disease caused by the gradual wear and tear of cartilage due to aging, overuse of the joints, and trauma, and its prevalence is continuously rising along with the increase in the elderly population.
[0003] In particular, rheumatoid arthritis is a disease characterized by significant hyperplasia of the synovium and infiltration of inflammatory cells, and it is known that the bones and joints are destroyed by the hyperplasia of the synovium. It is known that most of the cells that increase during hyperplasia of the synovium are synovial fibroblasts and macrophages. Although the exact mechanism by which hyperplasia of the synovium occurs has not been elucidated to date, it is speculated that the cause is an increase in the rate of proliferation of synovial fibroblasts and a decrease in the apoptosis of synovial fibroblasts.
[0004] Meanwhile, existing arthritis treatments include non-steroidal anti-inflammatory drugs (NSAIDs), steroids, immunosuppressants, and biological agents, which primarily focus on suppressing inflammatory responses or alleviating pain. However, these drugs have limitations; long-term use can cause various side effects such as gastrointestinal disorders, hepatotoxicity, and impaired immune function, and they cannot fundamentally inhibit the progression of the disease itself.
[0005] Therefore, there is a continuously growing need for safer and more effective new treatments for the prevention or treatment of arthritis. Recently, the development of arthritis treatments using novel pharmacological substances based on natural products, synthetic compounds, peptides, or proteins has been actively pursued; among these, there is particularly high interest in substances that can fundamentally produce therapeutic effects by selectively acting on the causative cells that trigger arthritis. Prior art literature
[0006] Korean Registered Patent No. 10-2531540 The problem to be solved
[0007] Accordingly, the inventors have completed the present invention by identifying that, as a result of diligent research efforts to develop a safe and effective treatment for arthritis, the N-dodecyl-4-hydroxybenzamide of the present invention has excellent effects in inhibiting differentiation and activity of synovial fibroblasts and macrophages in an arthritis model when treated, and can be usefully utilized in the treatment of arthritis through its efficacy in excellently inhibiting the expression of various cytokines and genes involved in inflammatory responses.
[0008] Accordingly, one objective of the present invention is to provide a pharmaceutical composition for the prevention or treatment of arthritis.
[0009] In addition, another objective of the present invention is to provide a food composition for the prevention or improvement of arthritis.
[0010] In addition, another objective of the present invention is to provide a veterinary composition for the prevention or treatment of arthritis.
[0011] In addition, another objective of the present invention is to provide a feed composition for the prevention or improvement of arthritis.
[0012] In addition, another objective of the present invention is to provide a medium composition for inhibiting the activity of synovial fibroblasts and macrophages. means of solving the problem
[0014] The terms used in this specification are for illustrative purposes only and should not be interpreted as being limiting. Singular expressions include plural expressions unless the context clearly indicates otherwise. In this specification, terms such as "comprising" or "having" are intended to indicate the existence of the features, numbers, steps, actions, components, parts, or combinations thereof described in the specification, and should be understood as not precluding the existence or addition of one or more other features, numbers, steps, actions, components, parts, or combinations thereof.
[0015] Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as generally understood by those skilled in the art to which the embodiments pertain. Terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with their meaning in the context of the relevant technology, and should not be interpreted in an ideal or overly formal sense unless explicitly defined in this application.
[0017] The present invention will be described in more detail below.
[0019] According to one aspect of the present invention, the present invention provides a pharmaceutical composition for the prevention or treatment of arthritis comprising, as an active ingredient, a compound represented by the following chemical formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof:
[0020] [Chemical Formula 1]
[0021] .
[0022] The compound represented by the above chemical formula 1 of the present invention is a compound having the IUPAC name N-dodecyl-4-hydroxybenzamide (CAS Number 146501-46-4).
[0023] Although research on the specific pharmacological activity of the above compound is still ongoing, it has not been determined whether it has a direct preventive and therapeutic effect on arthritis (preferably rheumatoid arthritis). In the present invention, it was first discovered that N-dodecyl-4-hydroxybenzamide, a compound represented by Chemical Formula 1, has an excellent therapeutic effect in mice with induced rheumatoid arthritis as a new use.
[0024] The above arthritis may include any arthritis known in the art, provided that the compound represented by Formula 1 of the present invention, its pharmaceutically acceptable salt, its hydrate, or its solvate exerts the desired effect, and may be, for example, one or more selected from the group consisting of rheumatoid arthritis, osteoarthritis, degenerative arthritis, osteochondritis dissecans, joint ligament injury, meniscal injury, joint misalignment, avascular necrosis, and juvenile idiopathic arthritis, preferably rheumatoid arthritis, but not limited thereto.
[0025] The compound of Formula 1 contained as an active ingredient in the pharmaceutical composition of the present invention may exist in the form of a pharmaceutically acceptable salt.
[0026] The term "pharmaceuticalally acceptable salt" in this invention refers to any organic or inorganic addition salt of said compound at a concentration having a relatively non-toxic and harmless active effect on the patient, wherein the side effects caused by said salt do not impair the beneficial efficacy of said compound.
[0027] Acid addition salts are prepared by conventional methods, for example, by dissolving a compound in an excess amount of an aqueous acid solution and precipitating the salt using a water-miscible organic solvent, for example, methanol, ethanol, acetone, or acetonitrile. An equal molar amount of the compound and an acid or alcohol (e.g., glycol monomethyl ether) in water may be heated, and then the mixture may be dried by evaporation or the precipitated salt may be filtered by suction.
[0028] At this time, organic acids and inorganic acids may be used as free acids. Inorganic acids may include hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, tartaric acid, etc., and organic acids may include methanesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carboxylic acid, vanillic acid, hydroiodic acid, etc., but are not limited to these.
[0029] In addition, pharmaceutically acceptable metal salts can be prepared using a base. Alkali metal salts or alkaline earth metal salts are obtained, for example, by dissolving a compound in an excess amount of an alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and then evaporating and drying the filtrate. At this time, it is pharmaceutically suitable to prepare sodium, potassium, or calcium salts as the metal salts, but is not limited to these. In addition, the corresponding silver salt can be obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (e.g., silver nitrate).
[0030] Pharmaceutically acceptable salts of the compounds of the present invention comprise salts of acidic or basic groups that may be present in said compounds, unless otherwise indicated. For example, pharmaceutically acceptable salts may include sodium, calcium, and potassium salts of hydroxyl groups, and other pharmaceutically acceptable salts of amino groups include hydrobromide, sulfate, hydrosulfate, phosphate, hydrophosphate, dihydrogen phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulfonate (mesylate), and p-toluenesulfonate (tosylate) salts, and may be prepared through methods for preparing salts known in the art.
[0031] In addition, the above compound comprises, without limitation, solvates such as its pharmaceutically acceptable salts as well as possible hydrates that can be prepared therefrom. Solvents of the above compound may be prepared using methods known in the art.
[0032] Furthermore, the above-mentioned compound may be prepared in a crystalline or amorphous form, and if prepared in a crystalline form, it may be optionally hydrated or solvated. The present invention may include not only stoichiometric hydrates of the above-mentioned compound but also compounds containing varying amounts of water. The solvates of the above-mentioned compound according to the present invention include both stoichiometric solvates and non-stoichiometric solvates.
[0033] Meanwhile, the method of obtaining N-dodecyl-4-hydroxybenzamide or a pharmaceutically acceptable salt thereof used in the pharmaceutical composition of the present invention is not particularly limited, and may be chemically synthesized by a method known in the art or commercially available materials may be used.
[0034] The term "rheumatoid arthritis" in this invention refers to a condition that causes systemic inflammation in many tissues and organs, but primarily occurs in the flexible synovial membrane. Typical symptoms include fever, swelling, and joint pain. Rheumatoid arthritis is accompanied by pain, impedes movement, and can lead to the loss of function and mobility if not treated properly. The progression of the disease is associated with inflammation around the synovial membrane, where synovial cells swell due to a large amount of synovial fluid, and fibrous tissue develops within the synovial membrane. Furthermore, inflammation of the synovial membrane damages the joint cartilage, causes bone erosion, and can even destroy the joint. Pathologically, the progression of the disease is primarily accompanied by the destruction of articular cartilage and joint ankylosis. Additionally, inflammation may spread to the lungs, pericardium, pleura, and / or the sclera of the eye. Although the exact cause is unknown, it is believed to involve a complex interplay of genetic and environmental factors and is known as a systemic autoimmune disease presumed to be caused by autoimmunity. Clinical diagnosis can be made through symptoms, physical examinations, and X-ray imaging. Treatment methods include pharmacological and non-pharmacological approaches. Non-pharmacological treatments include physical therapy, orthoses, occupational therapy, and nutritional therapy; however, these methods cannot halt the progression of joint damage. Analgesics and anti-inflammatory drugs (such as steroids) used in pharmacological treatment suppress symptoms, but they also cannot stop the progression of joint damage. Consequently, there is no known treatment method that can fundamentally suppress or delay the onset of rheumatoid arthritis while simultaneously alleviating symptoms.
[0035] For example, the pharmaceutical composition of the present invention can inhibit the differentiation, activation, and / or proliferation of synovial fibroblasts and / or macrophages, which are causative cells of rheumatoid arthritis, and can inhibit the occurrence of inflammation by reducing the expression of one or more selected from the group consisting of RANKL (Receptor Activator of Nuclear Factor-κB Ligand), IL-1b (interleukin 1 beta), IL-6 (interleukin 6), TNF-α (tumor necrosis factor α) and iNOS (inducible nitric oxide synthase).
[0036] The above phenomena are major factors involved in the progression of rheumatoid arthritis, and since the pharmaceutical composition of the present invention can effectively suppress these phenomena, it can prevent rheumatoid arthritis, delay its onset, and alleviate the symptoms caused by it.
[0037] In a specific embodiment of the present invention, when N-dodecyl-4-hydroxybenzamide (LSW04), a compound of Formula 1 of the present invention, was treated to synovial fibroblasts and macrophages activated by LPS, it was confirmed that the expression of cytokines and related genes, which are measures of arthritis, was excellently inhibited compared to the control group (N-dodecyl-2-hydroxybenzamide (LSW03)).
[0038] This indicates that a composition comprising the compound of Formula 1 of the present invention, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof can exhibit excellent effects for the prevention or treatment of rheumatoid arthritis.
[0039] The term "prevention" in the present invention refers to any act of suppressing or delaying the occurrence, spread, and recurrence of rheumatoid arthritis by administering the pharmaceutical composition of the present invention, and "treatment" refers to any act of improving or beneficially changing the symptoms of the said disease by administering the pharmaceutical composition of the present invention.
[0040] In a specific embodiment of the present invention, the treatment may mean a reduction or alleviation of signs of rheumatoid arthritis, a reduction in the severity of the disease, a delay or slowing of the disease, a temporary palliation or stabilization of the disease state, and other beneficial results, but is not limited thereto.
[0041] The term "individual" in the present invention refers to an individual suspected of having rheumatoid arthritis, or who has developed or may develop rheumatoid arthritis, and includes all animals including humans, monkeys, cattle, horses, sheep, pigs, chickens, turkeys, quails, cats, dogs, mice, rats, rabbits, or guinea pigs, and the said disease can be effectively prevented or treated by administering the pharmaceutical composition of the present invention to these individuals. In addition, the pharmaceutical composition of the present invention can exhibit a synergistic effect by being administered in combination with existing therapeutic agents.
[0042] The term "administration" in this invention means providing a specific substance to a patient by any appropriate method, and the route of administration of the composition of this invention may be administered through any general route as long as it can reach the target tissue. It may be administered intraperitoneally, intravenously, intramuscularly, subcutaneously, intradermally, orally, locally, intranasally, intrapulmonaryly, or rectally, but is not limited thereto. Additionally, the pharmaceutical composition of this invention may be administered by any device capable of delivering the active substance to target cells. Preferred modes of administration and formulations include intravenous injections, subcutaneous injections, intradermal injections, intramuscular injections, drip infusions, etc. Injectable preparations can be manufactured using aqueous solvents such as physiological saline solution and Ringer's solution, vegetable oils, higher fatty acid esters (e.g., ethyl oleate), alcohols (e.g., ethanol, benzyl alcohol, propylene glycol, glycerin), etc., and may include pharmaceutical carriers such as stabilizers to prevent deterioration (e.g., ascorbic acid, sodium bisulfite, sodium pyrosulfite, BHA, tocopherol, EDTA, etc.), emulsifiers, buffers to adjust pH, and preservatives to inhibit microbial growth (e.g., phenylmercury nitrate, thimerosal, benzalkonium chloride, phenol, cresol, benzyl alcohol, etc.).
[0043] For example, the composition of the present invention may further include a pharmaceutically acceptable carrier, diluent, or excipient, and may be formulated and used in various forms according to conventional methods for each intended use, such as oral formulations like powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, and injectable formulations like sterile injectable solutions, and may be administered orally or through various routes including intravenous, intraperitoneal, subcutaneous, rectal, and local administration. Examples of suitable carriers, excipients, or diluents that may be included in such compositions include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. Additionally, the composition of the present invention may further include fillers, anticoagulants, lubricants, wetting agents, fragrances, emulsifiers, preservatives, etc.
[0044] Solid dosage forms for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid dosage forms are formulated by mixing at least one excipient, such as starch, calcium carbonate, sucrose, lactose, gelatin, etc., into the above composition. In addition, in addition to simple excipients, lubricants such as magnesium stearate and talc may be used.
[0045] Examples of oral liquid formulations include suspensions, liquid formulations, emulsions, syrups, etc., and in addition to commonly used simple diluents such as water and liquid paraffin, various excipients, such as humectants, sweeteners, flavorings, and preservatives, may be included.
[0046] Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. As non-aqueous solvents and suspensions, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used. As bases for suppositories, Witepsol, Macrogol, Tween 61, cocoa oil, laurin oil, glycerogelatin, etc., may be used. Meanwhile, injectable preparations may contain conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifiers, stabilizers, and preservatives.
[0047] The above formulation may be prepared by conventional mixing, granulation, or coating methods and may contain an active ingredient in the range of about 0.1 to 75 weight%, preferably about 1 to 50 weight%. A unit formulation for a mammal weighing about 50 to 70 kg contains about 10 to 200 mg of the active ingredient.
[0048] At this time, the composition of the present invention is administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" in the present invention refers to an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment and that does not cause side effects. The effective dose level may be determined based on factors including the patient's health status, type and severity of the disease, drug activity, sensitivity to the drug, method of administration, time of administration, route of administration and elimination rate, duration of treatment, drugs used in combination or concurrently, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as a single or multiple doses. It is important to administer an amount that obtains maximum effect with a minimum amount without side effects, taking all of the above-mentioned factors into consideration, and this can be easily determined by a person skilled in the art.
[0049] For example, since the dosage may be increased or decreased depending on the route of administration, severity of the disease, gender, body weight, age, etc., the above dosage does not limit the scope of the present invention in any way.
[0050] The preferred dosage of the compound of the present invention varies depending on the patient's condition and body weight, the severity of the disease, the form of the drug, the route of administration, and the duration, but can be appropriately selected by those skilled in the art. However, for a desirable effect, it is preferable to administer the compound of the present invention at a dose of 0.0001 to 100 mg / kg (body weight) per day, preferably 0.001 to 100 mg / kg (body weight). Administration may be administered once a day or in divided doses via oral or parenteral routes.
[0051] The composition for the prevention or treatment of rheumatoid arthritis of the present invention may be prepared into a pharmaceutical formulation using methods well known in the art so as to provide rapid, sustained, or delayed release of the active ingredient after administration to a mammal. In preparing the formulation, the active ingredient may be mixed or diluted with a carrier, or encapsulated within a carrier in the form of a container.
[0053] In addition, the present invention may provide a quasi-drug composition for the prevention or treatment of bone diseases comprising N-dodecyl-4-hydroxybenzamide (LSW04).
[0054] The term "quasi-drug" as used in the present invention refers to articles used for the purpose of diagnosing, treating, improving, alleviating, managing, or preventing diseases in humans or animals, among which the effect is milder than that of pharmaceuticals. For example, quasi-drugs under the Pharmaceutical Affairs Act are those excluding articles used for pharmaceutical purposes, and include products used for the treatment or prevention of diseases in humans or animals, and products that have a mild effect on the human body or do not act directly on it.
[0055] When the composition according to the present invention is used as an additive for quasi-drugs, the composition may be added as is or used together with other quasi-drugs or quasi-drug ingredients, and may be used appropriately according to conventional methods. The mixing amount of the active ingredient may be appropriately determined according to the purpose of use. In addition, the quasi-drug may include a topical skin preparation, and said topical skin preparation may be manufactured and used in the form of an ointment, lotion, spray, patch, cream, powder, suspension, gel, or gel, but is not limited thereto.
[0057] In addition, according to another aspect of the present invention, the present invention provides a food composition for the prevention or improvement of arthritis comprising, as an active ingredient, a compound represented by the above-described formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof.
[0058] The "improvement" of the present invention refers to any act of improving or benefiting the suspected symptoms of the target disease and the subject of the invention by using a composition comprising the compound of Formula 1 or a food-grade acceptable salt thereof.
[0059] In addition, the above-mentioned "food-grade acceptable salt" can be defined identically to the aforementioned pharmaceutically acceptable salt.
[0060] The above food composition includes compositions for all forms of food, such as health functional food, nutritional supplement, food additives, special medicinal food, and dietary supplement.
[0061] In the present invention, a health functional food refers to a group of foods to which added value has been imparted by using physical, biochemical, or biotechnological methods to make the functions of the food act or manifest for a specific purpose, or a food processed by designing it to sufficiently express in the body the in vivo regulatory functions regarding the regulation of biological defense rhythms, disease prevention, and recovery possessed by the food composition.
[0062] The health functional food of the present invention includes forms such as tablets, capsules, pills, or liquids, and there are no particular limitations on the types of said health functional food. Examples may be any one selected from the group consisting of drinks, dairy products, confectionery, seasonings, beverages, snacks, candies, ice cream and frozen desserts, breakfast cereals, nutrition bars, snack bars, chocolate products, processed foods, grain products, pasta, soups, sauces and dressings, confectionery products, oils and fat products, dairy drinks, milk drinks, soy milk, soy dairy-like products, frozen foods, cooked foods, alternative foods, meat products, cheese, yogurt, bread, rolls, yeast products, cakes, cookies, and crackers, but are not limited thereto, and include all health foods in the conventional sense.
[0063] In the present invention, the food composition can be prepared by methods commonly used in the art, and the composition can be prepared by adding raw materials and ingredients commonly added in the art. In addition, the formulation of the food composition can also be prepared without limitation as long as it is a formulation recognized as a food composition.
[0064] Foods according to the present invention include, for example, various types of food, beverages, chewing gum, tea, vitamin complexes, functional foods, etc. In addition, foods include, but are not limited to, special nutritional foods (e.g., infant formula, baby food, etc.), processed meat products, fish products, tofu products, jelly products, noodles (e.g., ramen, noodles, etc.), bread products, health supplements, seasoning foods (e.g., soy sauce, soybean paste, red pepper paste, mixed sauce, etc.), sauces, confectionery products (e.g., snacks), candies, chocolates, chewing gum, ice cream, dairy products (e.g., fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (various types of kimchi, pickled vegetables, etc.), beverages (e.g., fruit beverages, vegetable beverages, soy milk, fermented beverages, etc.), natural seasonings (e.g., ramen soup, etc.), and food additives. The above foods, beverages, or food additives may be manufactured by conventional manufacturing methods.
[0065] When the composition of the present invention is used as an additive to a health functional food, the composition may be added as is or used together with other health functional food ingredients, and may be used appropriately according to conventional methods. The amount of the active ingredient can be appropriately determined according to the purpose of use. Generally, when manufacturing food or beverages, the composition of the present invention may be added to the raw material in an amount preferably 50 parts by weight or less, more preferably 25 parts by weight or less. However, in the case of long-term consumption for the purpose of health control and hygiene, the above amount may be less than the above range, and since there is no problem in terms of stability, the active ingredient may be used in an amount greater than the above range.
[0066] In addition to containing the active ingredients of the present invention, the food or health functional food composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients, as in conventional food compositions. Examples of the above-mentioned natural carbohydrates are monosaccharides, e.g., glucose, fructose, etc.; disaccharides, e.g., maltose, sucrose, etc.; and polysaccharides, such as conventional sugars like dextrin, cyclodextrin, etc.; and sugar alcohols such as xylitol, sorbitol, erythritol, etc. The above-mentioned flavoring agents may advantageously include natural flavoring agents (thaumatin), stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.), and synthetic flavoring agents (saccharin, aspartame, etc.).
[0067] In addition, the food composition may contain, in addition to the active ingredients of the present invention, various nutritional agents, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. Furthermore, the food composition of the present invention may contain fruit pulp for the production of natural fruit juices, fruit juice beverages, and vegetable beverages.
[0068] Since the active ingredient of the present invention can exhibit an effect of improving bone function through the inhibition of synovial fibroblast and macrophage activity, it can be usefully utilized, for example, as a health functional food for the elderly or as a health functional food for promoting growth in the growth stage. At the same time, it can be used as a special medicinal food for patients suffering from reduced bone function.
[0069] At this time, the above active ingredient may be used in the food composition of the present invention in an amount of 0.01 to 100 weight%. The above type of food composition may be prepared in various forms according to conventional methods known in the art. For example, as a health food, it may be prepared in the form of gum, vitamin complex, tea, juice, and drink containing the active ingredient, and the food composition having the active ingredient as an active ingredient may be consumed by granulating, encapsulating, or powdering it. The functional food composition of the present invention may include ingredients that are typically added during food manufacturing, and may include, for example, proteins, carbohydrates, fats, nutrients, and seasonings.
[0070] For example, when manufactured as a drink, in addition to the active ingredients of the present invention, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, jujube extract, licorice extract, etc. may be additionally included.
[0071] The above food composition may contain various nutritional supplements, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, it may contain extracts for the production of natural fruit juices, fruit juice beverages, and vegetable beverages. These ingredients may be used independently or in combination.
[0072] In the case of long-term consumption for the purpose of health and hygiene or health control, the food composition of the present invention can be taken for a long period of time because there are no problems in terms of safety.
[0074] In addition, according to another aspect of the present invention, the present invention provides a veterinary composition for the prevention or treatment of arthritis comprising, as an active ingredient, a compound represented by the above-described formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof.
[0075] The veterinary composition according to the present invention may be administered according to a number of administration methods widely known in the art and may be adjusted to suit the treatment of each of these animals. These compositions may be in the form of a solution, or a suspension for oral administration or injection, or in a solid or semi-solid form, or in the form of a powder, capsule, granule, sugar-coated tablet, soft capsule, spray, caplet, pill, tablet, or paste. Depending on the formulation and drug, the veterinary composition may further include conventional pharmaceutical ingredients for preparing liquid or solid formulations to be administered orally or parenterally. In addition, in the case of formulations for oral administration, these formulations may be administered directly to animals and may be mixed into food, but are not limited thereto.
[0077] In addition, according to another aspect of the present invention, the present invention may provide a feed composition for preventing or improving arthritis comprising, as an active ingredient, a compound represented by the above-described formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof.
[0078] The above active ingredient can be prepared in the same way as in the case of the above pharmaceutical composition or food composition.
[0079] The feed composition of the present invention may be a feed additive or a compound feed.
[0080] The active ingredient of the present invention can exhibit an overall improvement effect due to the enhancement of bone function, so it may be included in a feed composition as a growth promoter for animals or livestock.
[0081] Specifically, the feed containing the active ingredient according to the present invention can be manufactured in various forms of feed known in the art, and preferably may include concentrated feed, roughage, or special feed.
[0082] Concentrated feeds include seed grains such as wheat, oats, and corn; bran, which is a byproduct obtained by refining grains and includes rice bran, wheat bran, and barley bran; oilseed meal, which is a byproduct obtained by extracting oil from soybeans, rapeseed, sesame, flaxseed, and coconut; residues such as residual starch, which is the main component of starch residue remaining after removing starch from sweet potatoes and potatoes; fish meal, fish residue; fish soluble, which is a concentrated fresh liquid obtained from fish; meat meal, blood meal, feather meal; skim milk powder; dried whey, which is the residue obtained when making cheese from milk and casein from skim milk; and animal feeds such as yeast, Chlorella, and seaweed.
[0083] Forage includes fresh fodder such as wild grass, pasture grass, and green cuts; root vegetables such as feed turnips, feed beets, and a type of turnip called lutebarger; silage, which is a stored feed made by filling a silo with fresh grass, green cut crops, and grains and fermenting them with lactic acid; hay made by cutting and drying wild grass and pasture grass; straw of livestock crops; and leaves of legumes.
[0084] Special feeds include mineral feeds such as shells and rock salt, urea feeds such as urea or its derivatives such as diuretic isobutane, feed additives and dietary supplements, which are substances added in small amounts to compound feed to supplement components that are prone to being lacking when only natural feed ingredients are mixed, or to improve the shelf life of the feed.
[0085] The feed composition according to the present invention may include various feed additives.
[0086] In the present invention, the term "feed additive" refers to a substance added to feed for the purpose of various effects, such as supplementing nutrients and preventing weight loss, improving the digestibility and utilization of fiber in the feed, improving milk quality, preventing reproductive disorders and improving conception rates, and preventing high-temperature stress during the summer. The feed additive of the present invention corresponds to an auxiliary feed under the Feed Management Act and may additionally include mineral preparations such as sodium bicarbonate (baking soda), bentonite, magnesium oxide, and complex minerals; mineral preparations that are trace minerals such as zinc, copper, cobalt, and selenium; vitamin preparations such as carotene, vitamin E, vitamins A, D, E, nicotinic acid, and vitamin B complex; protected amino acid preparations such as methionine and lysic acid; protected fatty acid preparations such as calcium salts of fatty acids; probiotics (lactic acid bacteria preparations); probiotics such as yeast cultures and mold fermentation products; and yeast preparations.
[0087] The feed composition according to the present invention is not particularly limited and can be applied to any individual intended for promoting overall bone function. The individual refers to animals, for example, non-primates (e.g., cattle, pigs, horses, cats, dogs, rats, and mice) and mammals including primates (e.g., monkeys, e.g., cynomolgous monkeys and chimpanzees). The individual is a livestock animal (e.g., horses, cattle, pigs, etc.) or a pet animal (e.g., dogs or cats).
[0088] The dosage of the feed composition according to the present invention will depend on a number of factors such as the animal's species, size, weight, and age. In principle, a typical dosage may be in the range of 0.001 to 10 g per animal / day, but is not limited thereto.
[0090] In addition, according to another aspect of the present invention, the present invention provides a medium composition for inhibiting the activity of synovial fibroblasts and macrophages comprising, as an active ingredient, a compound represented by the above-described formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof.
[0091] Since the composition of the present invention includes the above-described N-dodecyl-4-hydroxybenzamide (LSW04) as an active ingredient, the common details between the two are omitted to avoid excessive complexity in this specification. Effects of the invention
[0093] Since the composition of the present invention exhibits an effect of inhibiting the activity of synovial fibroblasts and macrophages, it can be usefully used as an active ingredient in an excellent preventive or therapeutic composition for arthritis, including rheumatoid arthritis. Brief explanation of the drawing
[0095] Figure 1 shows the process of synovial fibroblast separation. Figure 2 shows the results of drug analysis of LSW03 (control group) and LSW04 (experimental group) using LPS-inflammation-induced synovial fibroblasts. Figure 3 shows the results of measuring the CCK8 activity of the LSW04 drug. Figure 4 shows the results confirming the effect of the LSW04 drug on synovial fibroblast activation gene expression. Figure 5 shows the results confirming the effect of the LSW04 drug on macrophage activation gene expression. Figure 6 shows the ELISA results measuring the cytokine protein expression levels in macrophages according to the LSW04 drug. Figure 7 shows the NO assay results in macrophages according to the LSW04 drug. Specific details for implementing the invention
[0096] The present invention will be described in more detail below through examples. These examples are solely for illustrating the present invention, and it will be obvious to those skilled in the art that the scope of the present invention is not to be interpreted as being limited by these examples.
[0098] Preparation Example 1: Preparation of Administration Drug
[0099] N-dodecyl-4-hydroxybenzamide (hereinafter LSW04), the drug to be administered, and N-dodecyl-2-hydroxybenzamide (hereinafter LSW03), the control, were synthesized by the convergent conformation method by Molecules & Materials (Room E3-303, Industry-Academic Cooperation Building, 141 Gajeong-ro, Yuseong-gu, Daejeon).
[0100] [Chemical Formula 1]
[0101]
[0102] [Chemical Formula 2]
[0103]
[0105] Preparation Example 2: Isolation of synovial fibroblasts for the preparation of a rheumatoid arthritis model
[0106] The lower peritoneum of mice (C57BL / 6) was isolated and cleaved, and isolated synovial cells were isolated by treatment with collagenase (1.0 mg / ml DMEM) and used for synovial fibroblast function studies using LPS induction and drugs (Fig. 1).
[0108] Example 1. Candidate Drug Selection
[0109] In rheumatoid arthritis, macrophages and synovial fibroblasts are activated and proliferate upon stimulation by antigens such as LPS, causing hypertrophy of the synovial tissue and producing various substances that induce inflammation. Accordingly, to analyze drugs using synovial fibroblasts activated by LPS, candidate drugs LSW03 and LSW04 were treated. As shown in Figure 2, the expression of TNF-α, IL-6, and iNOS was significantly suppressed in the LSW04 treatment group (10 uM), whereas the expression of these cytokines was not suppressed in the LSW03 treatment group (10 uM).
[0110] Accordingly, the drug LSW04 was selected as the active ingredient of the present invention, and LSW04 was used in the following examples.
[0112] Example 2. Analysis of the effect of LSW04 drug on synovial fibroblast apoptosis
[0113] To analyze the effect of the LSW04 drug on apoptosis in synovial fibroblasts, isolated synovial fibroblasts were treated with LPS (0.5 µg / ml) and various concentrations of the LSW04 drug, and CCK8 activity was measured. As shown in Figure 3, it was confirmed that there was no effect on more than 90% of the cells at a concentration of 50 µM.
[0115] Example 3. Analysis of the effect of LSW04 drug on synovial fibroblast activity
[0116] To analyze the effect of the drug LSW04 on the activity of synovial fibroblasts, changes in the expression of various cytokines and functional genes were measured after treating synovial fibroblasts with LPS and the drug LSW04 during the culture process. As shown in Figure 4, the drug LSW04 significantly inhibited the expression of RANKL and iNOS expressed by activated synovial fibroblasts.
[0118] Example 4. Analysis of the effect of LSW04 drug on macrophage activity
[0119] To analyze the effect of the LSW04 drug on macrophage activity, changes in the expression levels of various cytokines were measured after treating RAW264.7 cells (mouse macrophages) with LPS and the LSW04 drug. As shown in Figure 5, the LSW04 drug significantly inhibited the expression of the genes IL-1b, IL-6, TNF-α, and iNOS expressed under these conditions.
[0120] In addition, to analyze the protein expression levels of these substances, the concentrations of IL-1b, IL-6, and TNF-a in LPS-treated macrophage cultures were quantified using the ELISA method. As shown in Figure 6, it was confirmed that the LSW04 drug inhibited the protein synthesis of IL-1b, IL-6, and TNF-a in a manner similar to the inhibition of gene expression.
[0121] In addition, since the iNOS gene expression induced by LPS was inhibited by the LSW04 drug, NO, a functional product of iNOS, was measured. As shown in Figure 7, the concentration of NO in LPS-treated macrophages increased to 13 μM, but it was found that the production of NO was reduced to the control level by treatment with the LSW04 drug.
[0123] Synthesizing the above results, the LSW04 drug of the present invention inhibited the function of synovial fibroblasts and macrophages activated by LPS, thereby excellently inhibiting the expression of various cytokines and functional genes. In other words, since it has been proven that the LSW04 drug of the present invention can inhibit the activity of causative cells of rheumatoid arthritis, it can be utilized as a treatment for rheumatoid arthritis.
[0125] Foregoing, specific parts of the present invention have been described in detail. It is evident to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. Accordingly, the actual scope of the invention is defined by the appended claims and their equivalents.
Claims
Claim 1 A pharmaceutical composition for the prevention or treatment of arthritis comprising, as an active ingredient, a compound represented by the following chemical formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof: [Chemical Formula 1] . Claim 2 A pharmaceutical composition for the prevention or treatment of arthritis according to claim 1, characterized in that the arthritis is one or more selected from the group consisting of rheumatoid arthritis, osteoarthritis, degenerative arthritis, osteochondritis dissecans, joint ligament injury, meniscal injury, joint malalignment, avascular necrosis, and juvenile idiopathic arthritis. Claim 3 A pharmaceutical composition for the prevention or treatment of arthritis according to claim 1, wherein the compound represented by Chemical Formula 1, its pharmaceutically acceptable salt, its hydrate, or its solvate inhibits the differentiation, activation, or proliferation of synovial fibroblasts or macrophages. Claim 4 A pharmaceutical composition for the prevention or treatment of arthritis according to claim 1, wherein the compound represented by Chemical Formula 1, its pharmaceutically acceptable salt, its hydrate, or its solvate inhibits the expression of one or more selected from the group consisting of RANKL (Receptor Activator of Nuclear Factor-κB Ligand), IL-1b (interleukin 1 beta), IL-6 (interleukin 6), TNF-a (tumor necrosis factor α), and iNOS (inducible nitric oxide synthase). Claim 5 A food composition for the prevention or improvement of arthritis comprising, as an active ingredient, a compound represented by the following chemical formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof: [Chemical Formula 1] . Claim 6 A veterinary composition for the prevention or treatment of arthritis comprising, as an active ingredient, a compound represented by the following chemical formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof: [Chemical Formula 1] . Claim 7 A feed composition for the prevention or improvement of arthritis comprising, as an active ingredient, a compound represented by the following chemical formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof: [Chemical Formula 1] . Claim 8 A medium composition for inhibiting the activity of synovial fibroblasts and macrophages comprising, as an active ingredient, a compound represented by the following chemical formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof: [Chemical Formula 1] .
